Literature DB >> 10724796

Annual cost of erectile dysfunction to UK Society.

J M Plumb1, J F Guest.   

Abstract

OBJECTIVE: The objective of this study was to estimate the annual socioeconomic burden imposed by erectile dysfunction (ED) on UK society. DESIGN AND
SETTING: Health service resource use attributable to ED during 1997/1998 was obtained from appropriate databases and a panel of 22 hospital specialists comprising urologists, genito-urinary physicians, diabetologists and sexual health physicians. National unit resource costs at 1996/1997 prices were applied to the resource use data to estimate the annual National Health Service (NHS) cost of managing ED. A structured questionnaire pertaining to direct costs and absenteeism from work attributable to ED was mailed to a randomly selected sample of 5000 individuals who experience ED. MAIN OUTCOME MEASURES AND
RESULTS: During 1997/1998, the annual NHS cost was estimated to be 43.9 Pounds million for managing 113,600 men with ED. Outpatient visits were the major cost driver, accounting for 65% of the annual cost. Drugs prescribed by general practitioners (GPs) accounted for a further 25%. GP consultations and penile prosthetic surgery each accounted for 4%. Tests initiated by GPs accounted for 2%, while other resources accounted for less than 1%. The annual cost was sensitive to the number of outpatient visits and, to a lesser extent, to the number of prescriptions for ED treatments, but insensitive to changes in use of the other resources. Completed questionnaires were received from 23% (n = 1141) of the sample of individuals who experience ED. From the survey, it was estimated that the NHS managed 35% of individuals with ED in the last year. Assuming this to be representative, the total potential population of individuals with ED in the UK was estimated to be approximately 324,600 men. The total population of individuals with ED (n = 324,600 men) was estimated to incur 7.0 Pounds million annually in direct costs attributable to ED and to lose 19,630 days a year from work as a result of their ED, costing society 2.2 Pounds million in lost gross domestic product.
CONCLUSIONS: ED imposes a relatively small burden on UK society--53 Pounds million. Of this, 83% is borne by the NHS and 13% by patients. Indirect costs to society due to lost productivity account for the remaining 4%. The total NHS cost is strongly influenced by the number of hospital outpatient visits. Therefore, the future burden will depend largely on patients' eligibility to receive ED treatments on the NHS.

Entities:  

Mesh:

Year:  1999        PMID: 10724796     DOI: 10.2165/00019053-199916060-00008

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  12 in total

Review 1.  Pharmacotherapy in erectile dysfunction agents for self-injection programs and alternative application models.

Authors:  H Hedlund; P Hedlund
Journal:  Scand J Urol Nephrol Suppl       Date:  1996

2.  Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group.

Authors:  I Goldstein; T F Lue; H Padma-Nathan; R C Rosen; W D Steers; P A Wicker
Journal:  N Engl J Med       Date:  1998-05-14       Impact factor: 91.245

3.  Penile prosthesis implantation surgery: a statewide population based analysis of 2354 patients.

Authors:  F M Jhaveri; R Rutledge; C C Carson
Journal:  Int J Impot Res       Date:  1998-12       Impact factor: 2.896

4.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

Authors:  R C Rosen; A Riley; G Wagner; I H Osterloh; J Kirkpatrick; A Mishra
Journal:  Urology       Date:  1997-06       Impact factor: 2.649

Review 5.  The epidemiology of erectile dysfunction and its risk factors.

Authors:  A Bortolotti; F Parazzini; E Colli; M Landoni
Journal:  Int J Androl       Date:  1997-12

6.  Cost of schizophrenia to UK Society. An incidence-based cost-of-illness model for the first 5 years following diagnosis.

Authors:  J F Guest; R F Cookson
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

7.  Economic impact of using clodronate in the management of patients with multiple myeloma.

Authors:  N J Bruce; E V McCloskey; J A Kanis; J F Guest
Journal:  Br J Haematol       Date:  1999-02       Impact factor: 6.998

8.  Sildenafil, a novel effective oral therapy for male erectile dysfunction.

Authors:  M Boolell; S Gepi-Attee; J C Gingell; M J Allen
Journal:  Br J Urol       Date:  1996-08

9.  Increased incidence of depressive symptoms in men with erectile dysfunction.

Authors:  R Shabsigh; L T Klein; S Seidman; S A Kaplan; B J Lehrhoff; J S Ritter
Journal:  Urology       Date:  1998-11       Impact factor: 2.649

Review 10.  The epidemiology of erectile dysfunction.

Authors:  A E Benet; A Melman
Journal:  Urol Clin North Am       Date:  1995-11       Impact factor: 2.241

View more
  13 in total

1.  Health-related quality of life in a UK-based population of men with erectile dysfunction.

Authors:  Julian F Guest; Roben Das Gupta
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Lifestyle drugs: determining their value and who should pay.

Authors:  D Mitrany
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

4.  The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions.

Authors:  Edward C F Wilson; Emma S McKeen; Paul A Scuffham; Martin C J Brown; Kevan Wylie; Geoff Hackett
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  Prevalence and predictors of erectile dysfunction in adult male outpatient clinic attendees in Johor, Malaysia.

Authors:  Rusli Bin Nordin; Trived Soni; Amrina Kaur; Kean Por Loh; Shashi Miranda
Journal:  Singapore Med J       Date:  2018-05-18       Impact factor: 1.858

6.  Cost Effectiveness of Controlled-Release Oxybutynin Compared with Immediate-Release Oxybutynin and Tolterodine in the Treatment of Overactive Bladder in the UK, France and Austria.

Authors:  Julian F Guest; Dele Abegunde; Francis J Ruiz
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

Review 7.  The Quality of Life and Economic Burden of Erectile Dysfunction.

Authors:  Dean S Elterman; Samir K Bhattacharyya; Michael Mafilios; Emily Woodward; Krista Nitschelm; Arthur L Burnett
Journal:  Res Rep Urol       Date:  2021-02-18

8.  Cost of illness of hyponatremia in the United States.

Authors:  Audra Boscoe; Clark Paramore; Joseph G Verbalis
Journal:  Cost Eff Resour Alloc       Date:  2006-05-31

9.  Meta-Analysis of Prevalence of Erectile Dysfunction in Mainland China: Evidence Based on Epidemiological Surveys.

Authors:  Wenying Wang; Jingyuan Fan; Guifeng Huang; Xi Zhu; Ye Tian; Hua Tan; Li Su
Journal:  Sex Med       Date:  2016-12-23       Impact factor: 2.491

10.  Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.

Authors:  Maria Geitona; Hara Kousoulakou; Markos Ollandezos; Kostas Athanasakis; Sotiria Papanicolaou; Ioannis Kyriopoulos
Journal:  Ann Gen Psychiatry       Date:  2008-08-28       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.